Haleos Labs Q2 profit falls 73% as revenue rises 12%
Key highlights
- Haleos Labs’ Q2 revenue from operations rose 12% to Rs 91.3806 crore.
- Haleos Labs’ Q2 consolidated net profit fell 73% to Rs 1.7596 crore.
- Cost of materials consumed increased to Rs 49.5031 crore from Rs 39.0179 crore in Q2.
- Haleos Labs’ inventories rose to Rs 105.6315 crore at 30 September 2026 from Rs 79.8242 crore at 31 March 2026.
powered by IRIS

Haleos Labs Limited reported consolidated net profit of Rs 1.7596 crore for the quarter ended 30 September 2026, down 73% from Rs 6.4253 crore a year earlier, despite a 12% rise in revenue from operations to Rs 91.3806 crore. Total expenses increased faster than sales, reducing profit before tax to Rs 2.0085 crore.
Know Haleos Labs inside out
Results, valuation, peers and who's buying, in one view.
Why did Haleos Labs’ Q2 profit fall despite higher revenue?
Haleos Labs’ Q2 profit fell because expenses rose by more than revenue in the quarter ended 30 September 2026. Revenue from operations increased from Rs 81.3676 crore in the quarter ended 30 September 2025 to Rs 91.3806 crore, while total revenue, including other income, rose to Rs 91.4595 crore from Rs 81.7916 crore. Total expenses, however, increased to Rs 89.451 crore from Rs 73.2991 crore.
That cost movement reduced profit before tax to Rs 2.0085 crore from Rs 8.4925 crore a year earlier. Tax expense declined to Rs 24.89 lakh from Rs 2.0672 crore, but the lower tax charge did not offset the Rs 6.484 crore fall in pre-tax profit. Total comprehensive income was Rs 1.7862 crore, compared with Rs 6.4645 crore in the prior-year quarter.
Which Haleos Labs costs increased in the second quarter?
Haleos Labs recorded higher spending across most major expense categories in Q2. Cost of materials consumed increased to Rs 49.5031 crore from Rs 39.0179 crore a year earlier, an increase of Rs 10.4852 crore. Manufacturing expenses rose to Rs 18.4738 crore from Rs 17.3207 crore, while employee benefits expense increased to Rs 17.716 crore from Rs 16.2284 crore.
Other expenses increased to Rs 6.0375 crore from Rs 4.0444 crore, finance cost rose to Rs 2.147 crore from Rs 1.6153 crore, and depreciation and amortisation increased to Rs 4.2462 crore from Rs 3.8863 crore. Changes in inventories provided a credit of Rs 8.6726 crore, slightly lower than the Rs 8.8139 crore credit reported in the comparable quarter.
The sequential comparison also shows that higher sales did not increase quarterly profit. Revenue from operations rose from Rs 72.9423 crore in the quarter ended 30 June 2026 to Rs 91.3806 crore in Q2, but net profit fell from Rs 1.8403 crore to Rs 1.7596 crore. Materials cost increased from Rs 40.1381 crore to Rs 49.5031 crore, while other expenses rose from Rs 4.1561 crore to Rs 6.0375 crore.
What do Haleos Labs’ first-half results show?
Haleos Labs’ first-half profit declined while revenue from operations was broadly unchanged. For the half year ended 30 September 2026, revenue from operations was Rs 165.4611 crore, compared with Rs 163.8723 crore in the corresponding prior-year half. Net profit fell to Rs 3.6 crore from Rs 10.8074 crore, and profit before tax declined to Rs 5.4482 crore from Rs 15.5131 crore.
Materials and operating costs increased during the six months. Cost of materials consumed rose to Rs 90.7794 crore from Rs 66.7501 crore, and total expenses increased to Rs 160.5473 crore from Rs 149.7346 crore. Employee benefits were Rs 35.2652 crore versus Rs 32.5201 crore, finance cost was Rs 4.0466 crore versus Rs 3.4805 crore, and other expenses were Rs 10.1857 crore versus Rs 7.5366 crore.
Profit attributable to equity holders was Rs 5.9019 crore for the half year, compared with Rs 10.2595 crore a year earlier. The non-controlling interest reported a loss of Rs 2.302 crore, against profit of Rs 54.79 lakh in the previous corresponding period. Basic and diluted earnings per equity share, not annualised, were Rs 19.52 for the six months, down from Rs 33.93.
Got a follow-up? Ask IRIS
How did Haleos Labs’ balance sheet and cash flow change?
Haleos Labs’ total consolidated assets increased to Rs 499.6698 crore at 30 September 2026 from Rs 454.4084 crore at 31 March 2026. Inventories rose to Rs 105.6315 crore from Rs 79.8242 crore, trade receivables increased to Rs 75.2712 crore from Rs 61.3393 crore, and capital work-in-progress rose to Rs 30.0335 crore from Rs 10.4221 crore. Property, plant and equipment declined to Rs 258.5892 crore from Rs 266.5418 crore.
Borrowings increased over the six-month period. Non-current borrowings were Rs 60.2186 crore at 30 September 2026, compared with Rs 49.9579 crore at 31 March 2026, while current borrowings rose to Rs 73.3479 crore from Rs 58.8946 crore. Cash and cash equivalents ended the period at Rs 1.1807 crore, compared with Rs 1.2084 crore at the financial year-end.
Net cash inflow from operating activities was Rs 64.22 lakh for the half year ended 30 September 2026. Haleos Labs spent Rs 22.6638 crore on purchases of property, plant and equipment, producing net investing cash outflow of Rs 22.5512 crore. Financing activities generated Rs 21.8813 crore, including Rs 20.2945 crore of long-term borrowing proceeds and Rs 9.9864 crore of short-term borrowing proceeds.
What is included in Haleos Labs’ consolidated result?
Haleos Labs’ consolidated financial statements include Mahi Drugs Private Limited, its subsidiary, under Indian Accounting Standard 110, or Ind AS 110. The group operates in one reportable business segment, manufacturing active pharmaceutical ingredients and their intermediates. The filing therefore does not provide separate revenue or profit figures by product line or operating division.
Mahi Drugs reported total revenue of Rs 8.2959 crore and a net loss after tax of Rs 3.7391 crore for the quarter ended 30 September 2026, according to the auditor’s review report. The auditor said the subsidiary’s interim financial information was not material to the group and relied on management-certified information for it. The board approved the consolidated unaudited results on 11 November 2026, and the statutory auditors issued an unmodified conclusion.
Conclusion
Haleos Labs increased Q2 revenue from operations by 12%, but the Rs 16.1519 crore increase in total expenses exceeded the Rs 10.0129 crore increase in operating revenue. The result was a 73% year-on-year fall in quarterly net profit, while the half-year comparison showed a similar pattern of broadly stable revenue and lower profit.
The next results will show whether the rise in inventories to Rs 105.6315 crore, receivables to Rs 75.2712 crore and capital work-in-progress to Rs 30.0335 crore supports future sales and earnings. The filing also records Rs 22.6638 crore of first-half property, plant and equipment purchases and higher borrowings at 30 September 2026, without disclosing an earnings target or operational forecast.


